Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its e...

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...

Welcome to the Zombie-land Of Investing - Part II

In Part I of this research post, we highlight how the ES and Gold reacted 24+ months prior to the 2007-08 market peak and subsequent collapse in 2008-09. The point we were trying to push out to our followers was that the current US stock market indexes are acting in a very...

More smelters, scrap metal ban driving Chinese copper imports

Despite evidence of a slowing economy, shipments of raw materials are gliding across Chinese docks at a torrid pace, especially metals, which form the backbone of China’s industrial supply chain. In fact a recent report shows that, while Chinese imports are...

The Impact of Monetary Policy on Gold

In March, the World Gold Council released the newest edition of its Investment Update . What can we learn from the publication? Let’s examine the most recent history of Fed tightening and loosening with respect to its effect on gold prices. Is Fed&CloseCu...

dynaCERT Inc. CEO Interview on Bloomberg BNN

dynaCERT is expecting to turn ‘cash flow positive/profitable’ later this 2019 and appears poised to generate increasingly healthy returns thereafter. Global demand potential for dynaCERT's HG technology is in the multi-millions of units. Market Equities R...

This is Why the Secular Bull is Going to Last

To me the most important engineering puzzle policy makers around the world have to solve for the years ahead is how to get the economic machine to produce economic well-being for most people when monetary policy does not work …. Ray Dalio Economies are human constructs, n...

Is Trump Reversing Course On Iran?

The Trump administration is attempting to dial down the tension with Iran, lowering the risk of military conflict and pushing for diplomatic negotiations. On Sunday, U.S. Secretary of State Mike Pompeo said that the U.S. was ready to negotiate with Iran with "no precondi...
1 2 3 4 5 6 7